Abstract: The invention provides at least one protein which has biochemical and immunological properties of a major allergen of Dermatophagoides farinae (Derf II).

Abstract: The invention provides a DNA encoding at least one part of genetic information of protein which has biochemical and immunological properties of a major allergen of Dermatophagoides farinae (Derf II).

Abstract: The invention provides a DNA encoding at least one part of genetic information of protein which has biochemical and immunological properties of a major allergen of Dermatophagoides farinae (Derf II).

Abstract: Amidinonaphthyl furancarboxylate derivatives of the formula I ##STR1## wherein A is a single bond or A denotes (a) a phenyl group, cyclopentyl group, or cyclohexyl group,(b) an alkenylphenyl group, alkylphenyl group, phenylalkenyl group, or phenylalkyl group wherein alkyl is C.sub.1 to C.sub.7 alkyl and alkenyl is C.sub.2 to C.sub.7 alkenyl,(c) a C.sub.1 to C.sub.18 alkyl or C.sub.2 to C.sub.7 alkenyl group which may be substituted by one or two substituents selected from C.sub.1 to C.sub.5 alkyl groups and quanidino groups, wherein an alkyl substituent together with the carbon atom to which it is attached may form a cycloalkyl ring having from 3 to 6 carbon atoms, or said C.sub.1 to C.sub.5 alkyl may itself be substituted by a C.sub.3 to C.sub.6 cycloalkyl ring, or(d) --(CH.sub.2).sub.n --NH--CO--(CH.sub.2).sub.n' wherein n and n' may be the same or different and represent an integer from 1 to 4; andwherein R denotes(e) a hydroxyl group,(f) a C.sub.1 to C.sub.

Abstract: The invention provides an anti Derf II monoclonal antibody selectively recognizing Derf II and belonging to an IgG or IgM class, the antibody being obtained by immunizing a mammal with Derf II antigen, which is derived from Dermatophagoides farinae.

Abstract: A method for the treatment of cerebrovascular contraction in mammals involving administration of a pharmaceutical composition containing as an effective ingredient a p-guanidinobenzoic acid derivative represented by the formula ##STR1## wherein R denotes a group represented by the formula ##STR2## or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Abstract: Amidine compounds of formula (I) ##STR1## and the pharmaceutically acceptable acid addition salts thereof are novel and are of use as anti-trypsin, anti-plasmin, anti-kallikrein, anti-thrombin and anti-complement agents which may be administered orally. These amidine compounds can be produced by the reaction between a carboxylic acid compound of formula (II) ##STR2## or a reactive intermediate thereof and 6-amidino-2-naphthol of formula (III) ##STR3## or preferably an acid addition salt thereof.

Abstract: Amidine compounds of formula (I) ##STR1## and the pharmaceutically acceptable acid addition salts thereof are novel and are of use as anti-trypsin, anti-plasmin, anti-kallikrein, anti-thrombin and anti-complement agents which may be administered orally. These amidine compounds can be produced by the reaction between a carboxylic acid compound of formula (II) ##STR2## or a reactive intermediate thereof and 6-amidino-2-naphthol of formula (III) ##STR3## or preferably an acid addition salt thereof.

Abstract: Amidine compounds of the formula ##STR1## and pharmaceutically acceptable acid addition salts thereof are novel compounds and are useful as powerful anti-trypsin, anti-plasmin, anti-kallikrein and anti-thrombin agents. They are also useful as a powerful anti-complement agent.

Abstract: Amidino compounds represented by the formula ##STR1## and pharmaceutically acceptable acid addition salts thereof are novel compounds and are useful as powerful antitrypsine, antiplasmin, antikallikrein and antithrombin agents. Having strong anti-C1 (C1r, C1s) activities and an anticomplement activity, they are also useful as anticomplement agents. These amidino compounds are prepared by usual esterification of carboxylic acid compounds represented by the formula ##STR2## with 6-amidino-2-naphthol and, if necessary, can be transformed into pharmaceutically acceptable acid addition salts thereof.

Abstract: Amidino compounds represented by the formula (I) ##STR1## and pharmaceutically acceptable acid addition salts thereof are novel compounds and are useful as powerful antitrypsine, antiplasmin, antikallikrein and anti-thrombin agents. Having strong anti-Cl (Clr, Cls) activities and an anticomplement activity, they are also useful as anticomplement agents. These amidino compounds are prepared by usual esterification of carboxylic acid compounds represented by the formula (II)R.sub.1 --COOH (II)with 4-(.beta.-amidinoethenyl)phenol represented by the formula (III) ##STR2## and, if necessary, can be transformed into pharmaceutically acceptable acid addition salts thereof.

Abstract: Amidino compounds represented by the formula ##STR1## and pharmaceutically acceptable acid addition salts thereof are novel compounds and are useful as powerful antitrypsine, antiplasmin, antikallikrein and antithrombin agents. Having strong anti-C1 (C1r, C1s) activities and an anticomplement activity, they are also useful as anticomplement agents. These amidino compounds are prepared by usual esterification of carboxylic acid compounds represented by the formula ##STR2## with 6-amidino-2-naphthol and, if necessary, can be transformed into pharmaceuticlly acceptable acid addition salts thereof.

Abstract: A prolylphenylalanylarginine derivative represented by the formula, ##STR1## wherein R.sub.1 represents hydrogen or benzoyl; R.sub.2 represents naphthyl or 6-bromo-2-naphthyl. The above compound is useful as an excellent substrate for various enzymes, such as trypsin, plasmin, kallikrein, urokinase, Clesterase and the like. Accordingly, the activity of enzymes can be measured by use of said compound as a substrate.

Abstract: A phenylalanylvalylarginine derivative represented by the formula, ##STR1## wherein R.sub.1 represents hydrogen or benzoyl and R.sub.2 represents naphthyl. The above compound is useful as an excellent substrate for various enzymes, such as trypsin, plasmin, kallikrein, urokinase, Cl-esterase and the like. Accordingly, the activity of enzymes can be measured by use of said compound as a substrate.

Abstract: A valylleucyllysine derivative represented by the formula, ##STR1## wherein R.sub.1 represents hydrogen or benzoyl and R.sub.2 represented naphthyl. The above compound is useful as an excellent substrate for various anzymes, such as, trypsin, plasmin, kallikrein, urokinase, Cl-esterase and the like. Accordingly, the activity of enzymes can be measured by use of said compound as a substrate.

Abstract: Amino- or guanidino-1,2,3,4-tetrahydro-1-naphthoic esters represented by the formula, ##STR1## wherein R.sub.1 is --NH.sub.2 or ##STR2## R.sub.3 is --H, --R.sub.4, --O--R.sub.4, --NHCOCH.sub.3, a halogen, --CN, ##STR3## --COOH, --COOR.sub.4, ##STR4## or --(CH.sub.2).sub.n --COOCH.sub.2 --CO--R.sub.5 ; R.sub.5 is --O--R.sub.4, --NH.sub.2 or ##STR5## n is 0, 1 or 2, and R.sub.4 is a lower alkyl, or pharmaceutically acceptable acid addition salts thereof. Owing to their inhibitory activity on proteolytic enzymes the said esters and acid addition salts thereof are useful in the therapy of diseases caused by such enzymes.

Abstract: Amino- or guanidino-phenylpropionic ester derivatives represented by the formula: ##STR1## wherein R is --NH.sub.2 or ##STR2## R.sup.1 is hydrogen or a lower alkyl group, and R.sup.2 is an unsubstituted or a lower-alkyl-, carboxyalkyl-, lower-alkoxy-, lower-alkoxycarbonyl- or halogen-substituted phenyl group or an unsubstituted or a halogen-substituted naphthyl group, and acid addition salts thereof are novel compounds exhibiting a specific enzyme-inhibitory activity to proteolytic enzymes and, therefore, they are useful as the therapeutic agent of diseases induced by abnormal activation of these enzymes. The above-mentioned compounds can be produced by subjecting a nitrocinnamic acid derivative represented by the formula: ##STR3## and a phenol derivative or a naphthol derivative represented by the formula:HO--R.sup.